Litcius/Paper detail

Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis

Gregory C McDermott, Michael DiIorio, Yumeko Kawano, Mary Jeffway, M G MacVicar, Kumar Dahal, Su‐Jin Moon, Thany Seyok, Jonathan S. Coblyn, Elena Massarotti, Michael E. Weinblatt, Dana Weisenfeld, Katherine P. Liao

2024Seminars in Arthritis and Rheumatism10 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRheumatoid arthritisRefractory (planetary science)Biologic AgentsAntirheumatic AgentsInternal medicineOncologyArthritisImmunologyDermatologyAstrobiologyPhysicsRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsMultiple Sclerosis Research Studies
Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis | Litcius